Profiling of Early Immune Responses to Vaccination Using THP-1-Derived Dendritic Cells
Open Access
- 18 May 2024
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (10) , 5509
Abstract
The COVID-19 pandemic has made assessing vaccine efficacy more challenging. Besides neutralizing antibody assays, systems vaccinology studies use omics technology to reveal immune response mechanisms and identify gene signatures in human peripheral blood mononuclear cells (PBMCs). However, due to their low proportion in PBMCs, profiling the immune response signatures of dendritic cells (DCs) is difficult. Here, we develop a predictive model for evaluating early immune responses in dendritic cells. We establish a THP-1-derived dendritic cell (TDDC) model and stimulate their maturation in vitro with an optimal dose of attenuated yellow fever 17D (YF-17D). Transcriptomic analysis reveals that type I interferon (IFN-I)-induced immunity plays a key role in dendritic cells. IFN-I regulatory biomarkers (IRF7, SIGLEC1) and IFN-I-inducible biomarkers (IFI27, IFI44, IFIT1, IFIT3, ISG15, MX1, OAS2, OAS3) are identified and validated in vitro and in vivo. Furthermore, we apply this TDDC approach to various types of vaccines, providing novel insights into their early immune response signatures and their heterogeneity in vaccine recipients. Our findings suggest that a standardizable TDDC model is a promising predictive approach to assessing early immunity in DCs. Further research into vaccine efficacy assessment approaches on various types of immune cells could lead to a systemic regimen for vaccine development in the future.Keywords
Funding Information
- Universities Stable Funding Key Projects (WDZC20200821104802001, 2020YFA0908900, JCYJ20200109143018683)
- National Key Research and Development Program of China (WDZC20200821104802001, 2020YFA0908900, JCYJ20200109143018683)
- Shenzhen Science and Technology Research and Development Funds (WDZC20200821104802001, 2020YFA0908900, JCYJ20200109143018683)
- State Key Laboratory of Chemical Oncogenomics (WDZC20200821104802001, 2020YFA0908900, JCYJ20200109143018683)
- Institute of Biomedical Health Technology and Engineering of Shenzhen Bay Laboratory (WDZC20200821104802001, 2020YFA0908900, JCYJ20200109143018683)
This publication has 56 references indexed in Scilit:
- Immune cell interactions in tuberculosisCell, 2022
- A Review on Immunological Responses to SARS-CoV-2 and Various COVID-19 Vaccine RegimensPharmaceutical Research, 2022
- Tackling COVID-19 with neutralizing monoclonal antibodiesCell, 2021
- One year update on the COVID-19 pandemic: Where are we now?Acta Tropica, 2021
- Weak correlation between antibody titers and neutralizing activity in sera from SARS‐CoV‐2 infected subjectsJournal of Medical Virology, 2020
- Decline of SARS-CoV-2-specific IgG, IgM and IgA in convalescent COVID-19 patients within 100 days after hospital dischargeScience China Life Sciences, 2020
- A Comprehensive Map of the Monocyte-Derived Dendritic Cell Transcriptional Network Engaged upon Innate Sensing of HIVCell Reports, 2020
- Microbial Stimulation Fully Differentiates Monocytes to DC-SIGN/CD209+ Dendritic Cells for Immune T Cell AreasCell, 2010
- Pathogen Recognition and Innate ImmunityCell, 2006
- A cell line model for the differentiation of human dendritic cellsBiochemical and Biophysical Research Communications, 2005